Takeda Canada Reports Market Authorization For FRUZAQLA In Canada - Quick Facts
Takeda Canada said Health Canada has provided market authorization for FRUZAQLA, indicated for the treatment of adult patients with ...
Takeda's FRUZAQLA™ (fruquintinib) Receives Health Canada Market Authorization for Metastatic Colorectal Cancer (mCRC)
CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that Health Canada has provided market authorization for ...
pharmaphorum3mon
NICE turns down Takeda colorectal cancer drug
Takeda's recently approved advanced colorectal cancer therapy Fruzaqla has been rejected by NICE for use by the NHS on the grounds that it is not cost-effective. In draft guidance (PDF), the ...
Hosted on MSN19d
Li Ka-Shing-Backed Hutchmed Sells Stake in Unit for $608 Million
With three internally-discovered medicines marketed in China, it is building on momentum around Fruzaqla, its first cancer drug that broke into developed markets like the US, Europe and Japan via ...
Nasdaq1mon
Hutchmed to receive milestone payment from Takeda
Takeda received a national reimbursement recommendation for FRUZAQLA for patients with previously treated metastatic colorectal cancer in Spain in December 2024, the first national reimbursement ...